Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Defining definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The International Network of Obstetric Survey Systems study of uterine rupture: a descriptive multi-country population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fetal fraction of cell-free DNA in pregnancies after fresh or frozen embryo transfer following assisted reproductive technologies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multivitamin use and risk of preeclampsia in a high-income population: A cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  • MASP research group
View graph of relations

Objective: To study the effect of antenatal magnesium sulphate (MgSO 4) on cerebral palsy (CP) in a manner that also provides adequate power for a linked trial sequential analysis. Design: Double-blind, randomised, placebo-controlled, multi-centre trial. Setting: Fourteen Danish obstetric departments. Population: In total, 560 pregnant women at risk for preterm delivery before 32 weeks of gestation were randomised from December 2011 to January 2018. Those women gave birth to 680 children. Methods: Women were randomised to receive either a loading dose of 5 g MgSO 4 followed by 1 g/hour or a placebo in identical volumes. The children were followed up at a corrected age of 18 months or older with a review of their medical charts and with the Ages and Stages Questionnaire. Main outcome measure: The primary outcome measure was moderate to severe CP. Secondary outcomes included mortality, neonatal morbidity, blindness and mild CP. Results: The crude rates of moderate to severe CP in the MgSO 4 group and the placebo group were 2.0% and 3.3%, respectively. The adjusted odds of moderate to severe CP were lower in the MgSO 4 group than in the placebo group (odds ratio 0.61; 95% CI 0.23–1.65). Conclusions: Antenatal MgSO 4 before 32 weeks of gestation decreases the likelihood of moderate to severe CP; these results are entirely consistent with other randomised evidence summarised in the linked trial sequential analysis. Tweetable abstract: Antenatal magnesium sulphate may decrease the risk of moderate to severe cerebral palsy in children born before 32 weeks of gestation.

Original languageEnglish
JournalBJOG : an international journal of obstetrics and gynaecology
ISSN1470-0328
DOIs
Publication statusE-pub ahead of print - 1 Apr 2020

Bibliographical note

© 2020 Royal College of Obstetricians and Gynaecologists.

    Research areas

  • Cerebral palsy, magnesium sulphate, MgSO, mortality, neonatal morbidity, neuroprotection, preterm birth

ID: 59656468